Only complete language versions are shown.
If lung cancer progresses after previous treatment and carries a HER2-activating mutation, China has a matched trastuzumab rezetecan ADC pathway. Lu Shun's team at Shanghai Chest Hospital led related research and has reported clinical prescribing experience. Enquire about treatment, lung toxicity monitoring and costs; actual appointment availability must be confirmed.
Free initial service consultation · Understand your options and budget before you travel
2025 paper, data cut-off 2024-06-14; single-arm design and short follow-up cannot establish superiority to other HER2 medicines. View the evidence
HORIZON-Lung was a single-arm phase II study with relatively short follow-up; response rate is not cure rate. Drug costs use Tungwah's published prices on 2026-06-26, not current international patient quotes or full treatment costs. View sources
China approved trastuzumab rezetecan in May 2025 for eligible previously treated lung cancer, allowing patients with HER2-activating mutations to discuss a matched ADC as their next step.
The key is a HER2 (ERBB2)-activating mutation, not merely HER2 expression or amplification. Patients must also meet the adult advanced lung cancer criteria after at least one systemic treatment.
Lu Shun's team at Shanghai Chest Hospital led HORIZON-Lung and has reported clinical prescriptions for the drug. You can enquire about suitability and monitoring; actual appointment availability must be confirmed.
Estimated for fully self-funded foreign patients without Chinese health insurance or free-drug assistance. Include weight-based drug costs together with infusions, blood tests, chest imaging and supportive care in the ongoing budget.
Published by Tungwah on 2026-06-26; not an international patient quote. Calculated using whole vials every 3 weeks as in the study; actual prescriptions, delays and dose reductions affect costs.
Clarifying your disease type and previous treatment helps establish whether this option could form part of a plan for you.
The single-arm HORIZON-Lung study observed tumour responses and toxicities requiring careful management. Follow-up was relatively short. The probability of tumour shrinkage is not proof of longer survival or superiority to other HER2 medicines.
73% is an objective response rate, not a cure rate. The 5% refers only to lung disease recorded as serious adverse events, not the all-grade lung disease incidence.
Explore Shanghai teams whose research and clinical focus relate to your condition and may warrant further discussion.
HORIZON-Lung lead team
Lu Shun's team at Shanghai Chest Hospital led HORIZON-Lung, with Lu Shun as corresponding author. Hengrui's website records the team's clinical prescribing experience. You can enquire about HER2 mutation matching and subsequent monitoring; actual appointment availability must be confirmed.
Published research and clinical information can inform hospital selection; specific doctors, drug availability, international clinic charges and appointment dates are subject to confirmation by the hospital.
Tell us your diagnosis, previous treatments and main concerns. We help you communicate about Shanghai consultation requirements, budgets and travel arrangements.
You do not need to arrange new tests yourself for an initial consultation.
Costs, potential benefit and further treatment deserve specific answers before departure.
Not necessarily. This lung cancer indication requires a HER2 (ERBB2)-activating mutation, confirmed through a complete molecular report. Positive staining or amplification is not equivalent to an activating mutation.
No. In a single-arm study of 94 patients, 69 achieved an objective response, with median follow-up of 8.7 months. This is not a cure rate, does not establish superiority to other HER2 drugs and cannot guarantee individual benefit.
Do not decide to wait on your own. Contact the medical team immediately for new or worsening cough, breathlessness or fever to assess lung toxicity. A history of interstitial lung disease or radiation pneumonitis requires particular attention.
Ongoing assessment of response and toxicity is needed, with repeated infusions, blood tests and imaging. Study dosing was every 3 weeks; actual prescriptions, delays or dose reductions affect costs. Arrange drug supply and monitoring before returning home.
Starting with your condition and budget, we help communicate about consultations and treatment arrangements in Shanghai.
The initial service consultation is free; the treating doctor assesses your specific medical plan.
Information is compiled from public approval documents, studies and prices and does not replace an individual medical assessment. Research and cost figures each have a defined scope; published prices are not personal international patient quotes. Costs are discussed on a self-funded basis without Chinese health insurance or free-drug assistance.
Portraits and hospital images come from the cited public sources or existing project assets. Public accessibility does not constitute a commercial image licence.